



Press release

Swiss Takeover Board proceeding against certain shareholders regarding potential mandatory tender offer

Tel Aviv / Zurich, 11 August 2017 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced that it has been informed by the Swiss Takeover Board of an application and complaint of Nehama & Yoram Alroy Investment Ltd. and Elon Shalev regarding the potential duty of Himalaya (Cayman Island) TMT Fund and/or Himalaya Asset Management Ltd. and/or Mr. Xu Xiang and/or GF Fund Management Co. Ltd. and/or Zhuhai Hokai Medical Instruments Co. Ltd. and/or Mrs. Cai Mengke to make a mandatory tender offer according to art. 135 of the Swiss Financial Market Infrastructure Act. The applicants of the application and complaint claim the share price of such potential mandatory tender offer to be CHF 8.70 per share.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit our web site at www.shl-telemedicine.com.

For further information please contact:

Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.